New Target For Heart Failure Therapy Found
Posted on: Tuesday, 17 March 2009, 11:11 CDT
A novel signaling pathway plays a significant role in the production of aldosterone, a hormone that promotes heart failure after a myocardial infarction, according to a study conducted by Thomas Jefferson University researchers.The findings, which will be published online this week in Proceedings of the National Academy of Sciences, show that aldosterone production is mediated by a protein called beta-arrestin-1. Beta-arrestin-1 binds to angiotensin II receptors when they are activated by angiotensin II.
Aldosterone is secreted by the adrenal cortex. Its levels are elevated in chronic heart failure, and its presence contributes to morbidity and mortality of the disease. It contributes to heart failure progression and diminished cardiac function after myocardial infarction.
The production of aldosterone was previously thought to be solely the result of the activation of G-proteins, which are also activated when angiotensin II binds to its receptors, according to Anastasios Lymperopoulos, Ph.D., a Post-Doctoral Research Fellow in the Center for Translational Medicine and the George Zallie and Family Laboratory for Cardiovascular Gene Therapy at Jefferson Medical College of Thomas Jefferson University.
"The bottom line is that in order to effectively suppress aldosterone production, you need to inhibit beta-arrestin-1 in addition to inhibiting G-proteins," said Dr . Lymperopoulos, who is the lead author of the study.
All the drugs currently available for suppression of aldosterone by angiotensin II primarily target G-protein signaling pathways. However, Walter Koch, Ph.D., the W.W. Smith Professor of Medicine and the Director of the Center for Translational Medicine and the George Zallie and Family Laboratory for Cardiovascular Gene Therapy, said that these data clearly show that beta-arrestin1 plays a more significant role in aldosterone secretion than G-proteins.
"Aldosterone secretion is dependent on beta-arrestin-1," Dr. Koch said. "It may not be independent of G-proteins, but beta-arrestin-1 is definitely the critical player. The goal should be to find a new antagonist that can block beta-arrestin-1 and G-protein activation equally well. Doing so would lead to lower aldosterone levels at its source and alleviate negative remodeling processes in the injured heart."
---------
On The Net:
Thomas Jefferson University
Related Articles
- Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
- NIST Quantifies Low Levels Of 'Heart Attack Risk' Protein
- First and Only Weaning Product Based on 100% Non-Allergenic Amino-Acids Specifically Designed for Children With Cows' Milk Protein Allergy and Multiple Food Protein Intolerance
- MGP Ingredients Continues Transformation to Provider of Value-Added Products; Announces Significant Reduction in Commodity Protein and Starch Production
- Endothelial Cell Barrier Impairment Induced By Glioblastomas and Transforming Growth Factor [Beta]^Sub 2^ Involves Matrix Metalloproteinases and Tight Junction Proteins
- Meridian Bioscience Completes Acquisition of Recombinant Protein Technologies and Products From Vybion, Inc.
- Protein Design heart drug works well in trial
- Blood Protein Signals Heart Disease Risk
- Artery Cells Can Produce Heart Disease-Linked Protein
- Protein Hope for Bone Growth; Protein Hope for Bone Growth Excites
Rating: 2.9 / 5 (8 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds